≥99% HPLCIntranasal spray

Oxytocin + PT-141 (Nasal Spray)

Name: Oxytocin + PT-141 (Nasal Spray)
Brand: Dripfy
Availability: InStock

What it is?

Oxytocin + PT-141 is an investigational intranasal blend combining oxytocin, a neuropeptide investigated for this use, with PT-141 (bremelanotide), a melanocortin-receptor agonist. Bremelanotide is approved as an injectable medicine (Vyleesi) in the United States only — it has no marketing authorisation in the UK or EU — and this intranasal blend is not that approved product: it carries no approved indication, and it makes no claim to treat sexual dysfunction or any other condition. Delivered as a nasal spray, the blend sits within research on central arousal pathways.

Dripfy Advantage

Melanocortin signalling: PT-141 acts on melanocortin receptors (notably MC4R), a central pathway associated with sexual arousal.
Oxytocinergic angle: Oxytocin is investigated for its role in bonding and arousal-related signalling.
Central rather than vascular: Both components are studied for central-nervous-system arousal pathways rather than peripheral blood-flow mechanisms.
Physician-directed: Any regimen is determined solely by the supervising physician.

Research & Investigational Focus

Sexual desire and arousal: The melanocortin pathway is studied in relation to central sexual-arousal signalling; the intranasal blend itself is investigational, with no approved indication.
Central arousal signalling: Studied for central-pathway contributions to arousal in mixed-quality research.
Bonding-related neuropeptide effects: Oxytocin explored for social- and arousal-related signalling.

Composition & Formulation

Peptides: Oxytocin; PT-141 (bremelanotide)
Format: Intranasal spray
Purity: ≥99% by HPLC/MS
Supervision: Physician-directed use only

€622

Order by email

Submit an enquiry and we arrange the consultation, physician review and shipping. Physician recommendation required; not medical advice.

Purity: ≥99%
Form: Intranasal spray
Download Certificate of Analysis: Certificate of Analysis available on request

Important medical notice

A physician recommendation is mandatory before use.
The information on this website is educational only and is not medical advice, diagnosis, or treatment.
Always consult a qualified physician before starting any peptide.
Dosing is individualised and determined by your treating physician.

Peptide Practice Guide

Each card summarises what the peptide is studied for and its evidence strength. It is not a recommendation. Dosing and suitability are decided by your physician.

Oxytocin + PT-141 (Nasal Spray)

Oxytocin + melanocortin agonist (PT-141) intranasal blend (investigational) · Intranasal spray

C· Emerging evidence

PT-141 (bremelanotide) is a melanocortin-receptor agonist thought to act centrally at MC4R to influence sexual-arousal pathways. A subcutaneous injectable form of bremelanotide (Vyleesi) is approved in the United States only (it has no UK or EU marketing authorisation), and that approval does not extend to this intranasal blend. Oxytocin is a neuropeptide investigated for roles in bonding and arousal-related central signalling, though its evidence in this context is mixed. As an intranasal blend the combination is investigational, and the delivery route and pairing have not been established in robust trials, and it makes no claim to treat sexual dysfunction.

Studied use areas

Investigated for sexual desire and arousal (central pathways)
Studied for melanocortin-mediated arousal signalling
Explored for oxytocin's bonding- and arousal-related effects
Positioned for research on central (non-vascular) arousal mechanisms

Safety & status

Investigational blend; intranasal bremelanotide was studied in early clinical trials, but its development was halted after FDA concerns over blood-pressure increases (the approved product is subcutaneous), and evidence for the oxytocin pairing is limited and mixed
Use only under qualified physician supervision
PT-141 is associated with transient blood-pressure changes and nausea; not for use in uncontrolled hypertension, pregnancy, or breastfeeding

⚕ Clinical note: This intranasal oxytocin/PT-141 blend is not the approved bremelanotide product: although bremelanotide is approved in a different, injectable form in the United States only (with no UK or EU authorisation), that approval does not apply here. This blend carries no approved indication, is investigational, and its combination and route have not been validated in robust trials. It is for physician-directed use only, makes no claim to treat sexual dysfunction or any condition, is not medical advice, and is not proven to treat, cure, or prevent any condition.

Evidence: Grade C — early clinical / mixed evidence · References: Kingsberg et al., Obstetrics and Gynecology 2019; Clayton et al., Women's Health (London) 2016; Diamond et al., Journal of Sexual Medicine 2006 (intranasal bremelanotide); Magon and Kalra, Indian Journal of Endocrinology and Metabolism 2011